Pfizer Inc.
Pfizer Inc. (PFE)
Overview
Pfizer is one of the world's largest research-based pharmaceutical and biotechnology companies, developing, manufacturing, and marketing prescription medicines and vaccines across areas such as oncology, cardiology, immunology, vaccines, and rare disease. Headquartered in Manhattan, New York (at "The Spiral" tower), Pfizer traces its founding back to 1849, making it one of the oldest pharmaceutical companies in North America. The company reported full-year 2025 revenue of $62.6 billion and net income of $7.8 billion, with tens of thousands of employees operating across roughly 100 countries. Pfizer became a household name during the COVID-19 pandemic through its Comirnaty vaccine (developed with BioNTech) and Paxlovid antiviral, and it is now working through the post-pandemic decline in COVID-related sales while rebuilding its growth base through oncology, obesity, and other new-drug launches.
What They Do & How They Make Money
Pfizer makes money primarily by discovering, developing, and commercializing patented prescription drugs and vaccines, then selling them through wholesalers, distributors, pharmacies, hospitals, and government/public-health programs worldwide. Its business model is the classic "big pharma" model: heavy upfront investment in research and development and in acquiring promising drug candidates or entire biotech companies, offset by years of high-margin sales once a product is approved and under patent protection. Pfizer earns most of its money from branded, patent-protected medicines that command premium pricing; when patents expire and generic or biosimilar competition enters, revenue for that product typically falls sharply (a dynamic known in the industry as the "patent cliff"). To manage this, Pfizer continually invests in R&D and licensing/M&A (it has a long history of large acquisitions, including Warner-Lambert, Pharmacia, Wyeth, and more recently Seagen for antibody-drug-conjugate oncology technology) to refill its pipeline. A smaller but stable revenue stream comes from Pfizer CentreOne, its contract development and manufacturing business that produces medicines and biologics for other pharmaceutical companies.
Business Segments
Pfizer operates its core drug business as a single reportable operating segment — the "Global Biopharmaceuticals Business" (Biopharma) — but discloses revenue across three broad therapeutic-area groupings for transparency:
- Primary Care: includes vaccines (Comirnaty COVID-19 vaccine, Prevnar pneumococcal vaccine, Abrysvo RSV vaccine), Paxlovid, and other broadly prescribed medicines. This category has contracted sharply as COVID-19 product demand normalized, falling from a pandemic-era peak of over $70 billion (2022) to roughly $27 billion in 2025.
- Specialty Care: includes therapies for rare disease, inflammation/immunology, hospital/anti-infectives, and internal medicine — such as the Vyndaqel family for a cardiac condition (transthyretin amyloid cardiomyopathy) and Eliquis (co-marketed anticoagulant, one of Pfizer's best-selling drugs). Specialty Care revenue has grown steadily, reaching roughly $17.5 billion in 2025.
- Oncology: cancer therapies including Padcev, Lorbrena, Ibrance, and a growing biosimilars/oncology portfolio bolstered by the 2023 Seagen acquisition. Oncology revenue reached roughly $16.8 billion in 2025 and is a key strategic growth priority.
Alongside Biopharma, Pfizer CentreOne (contract manufacturing/distribution) contributes a smaller, more stable revenue stream (roughly $1.3 billion in 2025), and Pfizer Ignite is an early-stage initiative offering Pfizer's R&D and manufacturing expertise to biotech partners.
Competitors
- Broad pharma/biotech rivals: Johnson & Johnson, Merck & Co., Eli Lilly, AbbVie, Bristol Myers Squibb, Novartis, Roche, Sanofi, AstraZeneca, and GlaxoSmithKline
- Vaccines: Moderna, GlaxoSmithKline, Sanofi, and BioNTech (Pfizer's Comirnaty co-development partner, also a rival in some areas)
- Oncology: Merck (Keytruda), Bristol Myers Squibb, AstraZeneca, and Roche/Genentech
- Generics/biosimilars pressure: Viatris (formerly part of Pfizer via the Upjohn spin-off/merger), Teva, Sandoz, and other generic manufacturers that erode revenue once Pfizer drugs lose patent exclusivity
Competitive Position
Pfizer's competitive advantages include its scale, decades of regulatory and clinical-trial expertise, an extensive global commercial and distribution infrastructure, and a strong balance sheet that lets it acquire promising external science (as it did with Seagen for oncology and various smaller bolt-on deals) rather than relying solely on internal discovery. Its vaccines franchise (Prevnar, Abrysvo) and long-standing cardiology/rare-disease franchise (Vyndaqel, Eliquis) provide durable, less-commoditized revenue. However, Pfizer faces substantial headwinds: a significant "patent cliff" through the mid-2020s as several major drugs lose exclusivity, the sharp and continuing decline of COVID-19 product sales as the pandemic recedes into an endemic, lower-revenue market, and mounting biosimilar/generic competition. The company is also navigating U.S. drug-pricing policy risk (including potential tariffs on pharmaceutical imports and pressure from Medicare drug-price negotiation under the Inflation Reduction Act), which could compress margins on key products. Pfizer's strategic response has been to pivot new investment toward oncology and, more recently, the obesity/metabolic disease category (a major area of industry competition against Eli Lilly and Novo Nordisk), while pursuing cost-cutting and manufacturing-network optimization to protect margins as COVID-era windfall profits fade.